GSK’s U.S.-listed shares moved lower on April 29, 2026, down roughly 3% on the session, after the company published first-quarter results and commentary for 2026. The decline came despite management characterizing the quarter as a strong start to the year and reaffirming key elements of its full-year outlook.

GSK reported Q1 2026 sales of £7.6 billion, with strength in Specialty Medicines and Vaccines, while General Medicines declined. Investors focused on the mix of growth drivers and on items around legal settlement provisions/provisions that influenced reported profitability and added uncertainty around underlying earnings quality versus headline performance. GSK also reaffirmed its 2026 guidance ranges (including turnover growth of 3% to 5% and core operating profit growth of 7% to 9%), but the market reaction suggested the update did not provide a fresh positive catalyst versus expectations.

In the quarter, Specialty Medicines sales were £3.2 billion, with Respiratory/Immunology/Inflammation up and Oncology and HIV also higher. Vaccines sales were £2.1 billion, led by Shingrix at £1.0 billion, while Arexvy sales were £0.1 billion and declined versus the prior period. The combination of strong pockets (notably Shingrix and Specialty Medicines) and weak spots (including General Medicines and seasonality in RSV) shaped the day’s tone, as investors reassessed near-term growth durability.

Key near-term swing factors include any additional detail around legal provisions and how they flow through reported versus core results, updates on product momentum for Shingrix and Specialty Medicines, and forthcoming pipeline catalysts and regulatory milestones referenced in the Q1 materials. Investors will also monitor whether guidance proves conservative or tight as the year progresses, particularly as currency and policy-related uncertainties remain in focus.